

## PHARMACY BENEFIT PRIOR AUTHORIZATION UPDATES

8/23/2023

Below are upcoming updates to pharmacy benefit medication prior authorization criteria for Community Health Choice's Marketplace plans.

### Marketplace Premier Plans

Drug/Class	Effective Date	Overview
Linzess	9/1/2023	Adding indication of functional constipation (FC) in pediatric patients aged 6 to 17 years
Prevymis tab	9/1/2023	Adding indication for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (Donor CMV+/recipient CMV-)
Ayvakit	9/1/2023	Adding indication for the treatment of adult patients with indolent systemic mastocytosis (ISM)
Austedo/XR tab	9/1/2023	Adding the XR formulation to formulary with PA, Removing tetrabenazine (Xenazine) step for diagnosis of chorea associated with Huntington's disease
Radicava ORS/Starter Kit	9/1/2023	Changing FVC criterion to $\geq 60\%$
lapatinib (generic Tykerb)	9/1/2023	Adding oncology continuation criteria
Opzelura	9/1/2023	Adding allergist and immunologist to allowable specialists for diagnosis of atopic dermatitis
Zeposia/Starter Pack	9/1/2023	Updating step through agents for diagnosis of ulcerative colitis
Zejula	11/1/2023	Adding the tablet formulation to formulary with PA, Removing late-line treatment indication (withdrawn), Removing capsule quantity limit (QL) question
Lynparza	11/1/2023	Removing late-line treatment indication (withdrawn)
Rexulti	9/1/2023	Adding indication of agitation associated with dementia due to Alzheimer's disease
Xgeva	11/1/2023	Adding specialist prescriber requirement to hypercalcemia of malignancy indication, Removing IV bisphosphonate step

### Marketplace Select Plans

Drug/Class	Effective Date	Overview
Linzess	9/1/2023	Adding indication of functional constipation (FC) in pediatric patients aged 6 to 17 years
Prevymis tab	9/1/2023	Adding indication for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (Donor CMV+/recipient CMV-)
Ayvakit	9/1/2023	Adding indication for the treatment of adult patients with indolent systemic mastocytosis (ISM)
Austedo XR tab	9/1/2023	Adding to formulary with PA
Radicava ORS/Starter Kit	9/1/2023	Changing FVC criterion to $\geq 60\%$
lapatinib (generic Tykerb)	9/1/2023	Adding oncology continuation criteria
Zejula	11/1/2023	Adding the tablet formulation to formulary with PA, Removing late-line treatment indication (withdrawn), Removing capsule quantity limit (QL) question
Lynparza	11/1/2023	Removing late-line treatment indication (withdrawn)
Rexulti	9/1/2023	Adding indication of agitation associated with dementia due to Alzheimer's disease
Xgeva	11/1/2023	Adding specialist prescriber requirement to hypercalcemia of malignancy indication, Removing IV bisphosphonate step